
Plus Therapeutics: A Look at Our Second Quarter 2024 Financial Results and Exciting Business Updates!
Positive Interim ReSPECT-LM Phase 1 Data for Rhenium (186 Re) Obisbemeda for Leptomeningeal Metastases Presented Positive Topline Clinical Trial Results for CNSide diagnostic in the FORESEE trial Management to host conference call August 14, 2024 at 5:00 p.m. ET AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical…